Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells
Overview
- Phase
- Not Applicable
- Intervention
- IVIg
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Gene expression profile
- Last Updated
- 7 years ago
Overview
Brief Summary
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP. The investigators used a transcriptomic approach to compare the gene expression profiles in the peripheral blood of patients having a CIDP or autoimmune diseases, before and after IVIg treatment, in order to identify their mechanism of action in this condition, to lead to a better understanding of CIDP pathophysiology, and potentially determine factors associated with the response to the treatment.
Detailed Description
We study the change of the: * gene profile on transcriptome analysis of peripheral blood * T cell repertory * igG dosage * immunological profile Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune diseases. We also search for polymorphism of FCgammareceptor, TKPC et CASP3 genes in CIDP patients
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
IVIg
Intervention: IVIg
Outcomes
Primary Outcomes
Gene expression profile
Time Frame: 3 weeks
Change of the gene expression profile of a peripheral blood sample collected. just before IVIg administration (T1), and 3 weeks after IVIg treatment (T2)
Secondary Outcomes
- Gene expression profile in each lymphocytary sub-group(3 weeks)
- IgG(3 weeks)